Difference between revisions of "Prostate cancer, BRCA-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) |
||
| Line 36: | Line 36: | ||
! style="width: 20%" |Comparator | ! style="width: 20%" |Comparator | ||
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| − | |||
| − | |||
| − | |||
|- | |- | ||
|[http://doi.org/10.1056/NEJMoa1911440 de Bono et al. 2020 (PROfound)] | |[http://doi.org/10.1056/NEJMoa1911440 de Bono et al. 2020 (PROfound)] | ||
| Line 44: | Line 41: | ||
| style="background-color:#1a9851" |Phase 3 (E-RT-ooc) | | style="background-color:#1a9851" |Phase 3 (E-RT-ooc) | ||
|1. [[#Abiraterone_monotherapy|Abiraterone]]<br> 2. [[#Enzalutamide_monotherapy|Enzalutamide]] | |1. [[#Abiraterone_monotherapy|Abiraterone]]<br> 2. [[#Enzalutamide_monotherapy|Enzalutamide]] | ||
| − | | style="background-color:# | + | | style="background-color:#91cf60" |Seems to have superior OS<sup>1</sup><br>Median OS: 19.1 vs 14.7 mo<br>(HR 0.69, 95% CI 0.50-0.97) |
| − | |||
| − | |||
| − | |||
|- | |- | ||
|} | |} | ||
| − | ''<sup>1</sup> | + | ''<sup>1</sup>Reported efficacy is for patients in Cohort A in the 2020 update.'' |
| + | ====Prior treatment criteria==== | ||
| + | *Progression on abiraterone or enzalutamide | ||
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
Revision as of 11:02, 21 August 2022
| Page editor | Section editor | ||
|---|---|---|---|
 |
Laura S. Graham, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA  LauraGrahamMD
|
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA arkhaki
|
7 regimens on this page
8 variants on this page
|
Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.
Metastatic castration-resistant
Olaparib monotherapy
Regimen Variant #1, 300 mg BID
| FDA-recommended dose |
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| de Bono et al. 2020 (PROfound) | 2017-2018 | Phase 3 (E-RT-ooc) | 1. Abiraterone 2. Enzalutamide |
Seems to have superior OS1 Median OS: 19.1 vs 14.7 mo (HR 0.69, 95% CI 0.50-0.97) |
1Reported efficacy is for patients in Cohort A in the 2020 update.
Prior treatment criteria
- Progression on abiraterone or enzalutamide
Biomarker eligibility criteria
- Cohort A: 1+ alterations in BRCA1, BRCA2, or ATM
- Cohort B: 1+ alterations in BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L
Targeted therapy
- Olaparib (Lynparza) 300 mg PO twice per day
Continued indefinitely
Regimen Variant #2, 400 mg BID
| Study | Evidence |
|---|---|
| Kaufman et al. 2014 (Study 42) | Phase 2, <20 pts in subgroup |
| Mateo et al. 2015 (TOPARP-A) | Phase 2 |
Biomarker eligibility criteria
- Study 42: Germline BRCA1/2 mutations and had progression on hormonal and one systemic therapy
- TOPARP-A: Patients who were found to have homozygous deletions, deleterious mutations, or both in DNA-repair genes were much more likely to respond to olaparib
Targeted therapy
- Olaparib (Lynparza) 400 mg PO twice per day
Continued indefinitely
References
- Study 42: Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains verified protocol link to PMC article PubMed NCT01078662
- TOPARP-A: Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697-708. link to original article contains verified protocol link to PMC article PubMed NCT01682772
- PROfound: de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. link to original article contains verified protocol link to supplementary appendix PubMed NCT02987543
- Update: Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. Epub 2020 Sep 20. link to original article PubMed
Rucaparib monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Awaiting publication (TRITON2) | 2017-NR | Phase 2 (RT) |
Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.
Targeted therapy
References
- TRITON2: NCT02952534